Summary
The product TESTO C250, manufactured by EOQ Remedies, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number VTS744, was submitted by EOQ Remedies and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis confirmed the presence of Testosterone Cypionate, with a measured concentration of 272.55 mg/ml, exceeding the labeled claim of 250 mg/ml by 9.02%.
The testing process began on 6 November 2024, with the sample received on 15 November 2024, and analysis completed on 18 November 2024. While the results confirm accurate dosing, reseller-submitted samples require scrutiny to ensure reliability, as they may represent selective batches. Independent third-party testing remains critical to validate these findings across multiple product batches. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: EOQ Remedies
- Product Name: TESTO C250
- Active Ingredient: Testosterone Cypionate
- Batch Number: VTS744
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #52831
- Testing Ordered: 6 November 2024
- Sample Received: 15 November 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: EOQ Remedies (Manufacturer)
- Analysis Paid For By: EOQ Remedies
Testing Results
- Specification: 250 mg/ml (as stated on the label)
- Measured Concentration: 272.55 mg/ml
- Accuracy: 109.02% (9.02% above the label claim)
- Variance: 9.02
Verification Details
- Verification URL: https://janoshik.com/tests/52831_SKAR3535B6UN
Evaluation of Reseller-Submitted Testing
This analysis highlights the accuracy of the tested product but warrants careful evaluation due to its submission and funding by EOQ Remedies. Resellers often select optimal batches for testing, which may not fully represent the consistency of products available to consumers. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, these findings would benefit from independent validation through third-party testing across multiple batches.
Conclusion
The analysis confirms that TESTO C250 is slightly overdosed, with a measured concentration of 272.55 mg/ml. This result reflects strong quality control for this batch but underscores the importance of additional testing to ensure consistent dosing across the product line. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding anabolic steroid products.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
